ICH Q11 Starting Material Selection: A Practical Guide for Pharmaceutical Intermediate Buyers

Abstract: ICH Q11 defines where formal quality oversight begins in pharmaceutical manufacturing through “starting material” designation. For intermediate buyers, this designation determines supplier documentation requirements, impurity control responsibilities, and change management obligations.

This guide explains the key principles of starting material selection in plain language, clarifies the common misconception around “significant structural fragments,” distinguishes commercially available chemicals from custom-synthesized intermediates, and provides a practical checklist with five critical questions buyers should ask suppliers.

Understanding these rules helps procurement teams assess compliance risk, avoid costly regulatory delays, and make informed sourcing decisions.

What Is a Starting Material and Why Should Buyers Care?

When you purchase a pharmaceutical intermediate, you might assume the supplier handles all regulatory responsibilities. But under ICH Q11, the answer depends on a critical question: is that intermediate designated as a “starting material”?

A starting material is the point in a drug’s synthesis where formal quality oversight begins. Everything upstream of the starting material is considered “raw material” chemistry with less regulatory scrutiny. Everything from the starting material onward must follow strict manufacturing and quality standards.

For buyers, this matters because:

• Documentation depth changes: If your intermediate is a starting material, the supplier must provide detailed process information, impurity profiles, and quality specifications
• Change notifications become mandatory: Switching suppliers for a designated starting material may require regulatory filings
• Audit scope expands: You may need to understand not just your supplier’s facility, but also their upstream raw material sources

Understanding these boundaries helps you ask the right questions before placing an order. For a comprehensive framework on evaluating suppliers, see our Pharmaceutical Intermediate Supplier Audit Checklist.

The “Significant Structural Fragment” Misconception

One of the most misunderstood concepts in ICH Q11 is the term “significant structural fragment.” Many buyers—and even some suppliers—believe this means the starting material must structurally resemble the final active pharmaceutical ingredient (API).

This is incorrect.

ICH Q11 uses this phrase simply to distinguish starting materials from reagents, catalysts, and solvents. A starting material contributes a meaningful portion of the API’s molecular structure, but it doesn’t need to look like the API.

Why does this matter for procurement? Because some suppliers may claim their intermediate qualifies as a starting material based on structural similarity alone—without meeting the other Q11 criteria. If regulators later reject that designation, your project could face significant delays.

The real test isn’t structural similarity. It’s whether the intermediate’s upstream process affects the API’s impurity profile. If impurities formed upstream carry through to the API, those steps should be under formal quality oversight.

Commercially Available vs Custom Synthesized: Why It Matters

ICH Q11 makes an important distinction that directly affects your sourcing strategy:

Commercially available chemicals are compounds that exist in the non-pharmaceutical market—produced by multiple suppliers, available as commodity chemicals. These can be designated as starting materials without extensive justification. Examples include common organic acids, widely-used building blocks, and simple amino acid derivatives.

Custom-synthesized intermediates are compounds made specifically for pharmaceutical manufacturing. They don’t exist in a commodity market. If you want to designate one as a starting material, you must provide a scientific justification demonstrating compliance with all Q11 principles.

For buyers, this creates a practical decision:

If your project uses a custom-synthesized intermediate, ask your supplier whether they’ve already prepared Q11 justification documentation. If they haven’t, factor the time and cost of preparing it into your project timeline.

5 Questions to Ask Your Supplier About Starting Material Status

1. “Has this intermediate been designated as a starting material in any approved regulatory filing?”
   If yes, request the reference. If no, you’ll need to prepare the justification yourself.
2. “How many chemical transformation steps are between this intermediate and the API?”
   ICH Q11 expects multiple synthetic steps between the starting material and the API. Too few steps is a red flag for regulators—they want to see that the process includes enough controlled steps to ensure API quality.
3. “What is the impurity profile at this stage, and which impurities carry through to the API?”
   Impurities that persist through multiple steps and appear in the API must be controlled starting from this material. Learn how to evaluate this data in our guide on how to read a Certificate of Analysis.
4. “Is this compound available from other suppliers, or is it exclusively manufactured for pharmaceutical use?”
   This determines whether it qualifies as “commercially available” or requires full Q11 justification.
5. “What documentation can you provide to support a starting material designation?”
   Look for: process description, impurity mapping, analytical methods, and stability data. If the supplier can’t provide these, their starting material claim may not hold up under regulatory review. Our COA verification tools guidecan help you spot gaps.

What Happens When You Switch a Starting Material Supplier?

Switching suppliers for a designated starting material is not a simple procurement change. Depending on the nature of the switch, it may trigger regulatory obligations:

• Same route, same process: Potentially a minor change—internal documentation only
• Different synthetic route or different catalysts/solvents: Likely a moderate change requiring comparative studies and regulatory notification
• Different impurity profile: May require full re-qualification, including stability studies and analytical method revalidation

A real-world example: A Chinese API manufacturer switched starting material suppliers. The new supplier used a different synthetic route, different catalyst loading, and a new solvent system. After comparative studies—including impurity profiles, process validation, three commercial-scale batches, and both accelerated and long-term stability testing—regulators classified this as a moderate change requiring provincial-level filing.

Practical takeaway: Before switching, request a side-by-side comparison of synthetic routes, impurity profiles (HPLC chromatograms), residual solvents data, and chiral purity results. For chiral compounds, see our chiral purity and enantiomeric excess guide. For consistency concerns, our article on batch-to-batch consistency provides additional context.

COA Red Flags Related to Starting Material Status

Your supplier’s Certificate of Analysis can reveal whether their starting material claim is credible. Watch for these five red flags:

1. Missing impurity specifications: A legitimate starting material should have defined impurity limits—not just “passes test”
2. No chiral data for chiral compounds: If the intermediate has a stereocenter, the COA must include enantiomeric excess data
3. No residual solvent information: Solvents from upstream steps should be controlled and reported
4. Vague method references: “By HPLC” without specifying the method is insufficient for a starting material
5. No stability data or retest date: Starting materials should have defined retest periods—see our intermediate storage conditions guide

Additionally, if your starting material involves metal catalysts, check for elemental impurities data per ICH Q3D—a missing metals screen is a common gap in supplier documentation.

Practical Buyer’s Checklist

Before finalizing any intermediate purchase, confirm:

• ☐ The supplier can clearly state whether the compound is a designated starting material
• ☐ If custom-synthesized, Q11 justification documentation is available
• ☐ Multiple chemical transformation steps exist between the intermediate and the API
• ☐ The COA includes specific impurity specifications, not just pass/fail results
• ☐ Residual solvent and elemental impurity data are provided
• ☐ The supplier has a documented change control process for route modifications
• ☐ Stability or retest data supports the proposed storage period

FAQ

What is ICH Q11?
ICH Q11 is an international guideline that describes how to develop and manufacture drug substances (APIs). Its section on starting materials defines where formal quality oversight begins in the synthesis chain.

Can any intermediate be a starting material?
No. The intermediate must meet all Q11 principles, including having a significant structural fragment, multiple downstream transformation steps, and adequate impurity control. Simply being an intermediate doesn’t automatically qualify it.

Do I need to audit my starting material supplier’s upstream suppliers?
Generally, no—if the starting material is properly designated. The starting material boundary exists precisely so you don’t need to trace quality oversight further upstream. However, you should understand the general synthetic route and potential impurity sources.

What’s the difference between a starting material and an intermediate?
A starting material is a specific type of intermediate that marks the beginning of regulated manufacturing. Not all intermediates are starting materials—some are earlier building blocks with less formal oversight.

What happens if I switch my starting material supplier?
Switching suppliers for a designated starting material may trigger regulatory obligations depending on the change. If the synthetic route, catalysts, or solvents differ, you likely need bridging studies and regulatory notification. Always compare impurity profiles, residual solvents, and chiral purity before and after the switch.

Tianming Service Team：sunqian0123@gmail.com